Abstract
Acrylamide is converted to glycidamide as a reactive metabolite by the monooxygenase isozyme CYP2E1. Since the latter is known to be induced in diabetic patients, increased acrylamide toxicity in such patients is suspected. Differences in acrylamide toxicokinetics in non-diabetic and diabetic rats receiving acrylamide (50 mg/kg) orally or via i.p. injection were investigated in this report. Blood was collected at various time points, acrylamide and glycidamide in plasma were determined by reversed-phase high-performance liquid chromatography, and the data were analyzed for toxicokinetic parameters using the proper software. Mean maximum plasma concentration, the apparent clearance, and area under the curve in non-diabetic rats were significantly higher than in diabetics, an important fact to be considered in xenobiotic exposure of diabetic individuals.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
